Investments, Lpwong Roderic... Net Worth

The estimated Net Worth of Investments, Lpwong Roderic... is at least $323 Milion dollars as of 11 May 2021. Investments Roderic owns over 725,000 units of Rocket Pharmaceuticals Inc stock worth over $294,206,065 and over the last 6 years Investments sold RCKT stock worth over $29,021,750.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Investments Roderic RCKT stock SEC Form 4 insiders trading

Investments has made over 4 trades of the Rocket Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Investments sold 725,000 units of RCKT stock worth $29,021,750 on 11 May 2021.

The largest trade Investments's ever made was selling 725,000 units of Rocket Pharmaceuticals Inc stock on 11 May 2021 worth over $29,021,750. On average, Investments trades about 291,288 units every 126 days since 2018. As of 11 May 2021 Investments still owns at least 15,460,119 units of Rocket Pharmaceuticals Inc stock.

You can see the complete history of Investments Roderic stock trades at the bottom of the page.

What's Investments Roderic's mailing address?

Investments's mailing address filed with the SEC is 412 W 15th St FLOOR 9C/O, New York, NY 10011, USA.

Insiders trading at Rocket Pharmaceuticals Inc

Over the last 7 years, insiders at Rocket Pharmaceuticals Inc have traded over $45,364,690 worth of Rocket Pharmaceuticals Inc stock and bought 2,407,332 units worth $48,979,646 . The most active insiders traders include Investments, Lpwong Roderic..., Mikael Dolsten oraz Investments, Lpwong Roderic.... On average, Rocket Pharmaceuticals Inc executives and independent directors trade stock every 30 days with the average trade being worth of $1,269,815. The most recent stock trade was executed by John Militello on 16 August 2024, trading 1,064 units of RCKT stock currently worth $19,684.

What does Rocket Pharmaceuticals Inc do?

rocket pharmaceuticals, ltd is a biotechnology company focused on seeking cures through molecular and gene therapy. we are developing first-in-class treatments for patients with rare and often devastating orphan diseases using a lentiviral-based gene therapy approach. we have developed rewarding partnerships with a number of leading international research institutions as well as with centers of manufacturing and cell processing expertise, while building an internal team to drive the research, development, clinical and regulatory programs. ultimately we aim to launch and globally commercialize innovative gene therapies in disease areas with high unmet need. for more information, please visit www.rocketpharma.com.

Complete history of Investments Roderic stock trades at Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals Inc executives and stock owners

Rocket Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Gaurav Shah,
  President, Chief Executive Officer, Director
• Kinnari Patel,
  Chief Operating Officer and Head of Development
• Kamran Alam,
  Senior Vice President - Finance, Principal Financial Officer
• Jonathan Schwartz,
  Chief Medical Officer
• Dr. Gaurav D. Shah,
  CEO & Director
• Kinnari Patel M.B.A., Pharm.D., PharmD, MBA,
  Pres, COO & Head of Devel.
• Jonathan Schwartz,
  Chief Medical Officer & Sr. VP of Clinical Devel.
• John C. Militello CPA, CPA,
  VP, Sr. Controller & Principal Accounting Officer
• Roderick Wong,
  Chairman of the Board
• Pedro Granadillo,
  Independent Director
• Carsten Boess,
  Independent Director
• Naveen Yalamanchi,
  Independent Director
• Gotham Makker,
  Independent Director
• David Southwell,
  Director
• Elisabeth Bjork,
  Independent Director
• John Militello,
  Principal Accounting Officer and Senior Controller
• Dr. Gayatri R. Rao J.D., M.D.,
  Chief Devel. Officer of LVV & Sr. VP
• Isabel Carmona J.D.,
  Sr. VP & Chief HR Officer
• Kevin Giordano,
  Director of Corp. Communications
• Martin L. Wilson,
  Gen. Counsel, Chief Compliance Officer & Sr. VP
• Mayur Kasetty,
  Bus. Devel. & Operations and Investor Relations Lead
• Carlos Garcia-Parada M.B.A.,
  Chief Financial Officer
• Investments, Lpwong Roderic...,
  
• Mark Andrew White,
  See Remarks
• Investments, Lpwong Roderic...,
  
• Roderickrtw Investments, Lp...,
  
• Keith Woods,
  
• Fady Ibraham Malik,
  
• Carlos Garcia Parada,
  Chief Financial Officer
• Martin Wilson,
  General Counsel
• Mikael Dolsten,
  
• Aaron Ondrey,
  Chief Financial Officer